{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:39:04Z","timestamp":1772782744526,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003390","name":"Fritz Thyssen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003390","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Atheros Foundation"},{"name":"Amsterdams Universiteits Fonds"},{"name":"AmSTOL Foundation"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.atherosclerosis.2018.06.820","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T09:46:31Z","timestamp":1538127991000},"page":"327-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C"],"prefix":"10.1016","volume":"277","author":[{"given":"Xander M.","family":"van Delden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roeland","family":"Huijgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen H.","family":"Wolmarans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte C.","family":"Brice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer K.","family":"Barron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-5912","authenticated-orcid":false,"given":"Dirk J.","family":"Blom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. David","family":"Marais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A\u00a0receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Sci. (N. Y.)"},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s004390050243","article-title":"Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutations","volume":"98","author":"Steyn","year":"1996","journal-title":"Hum. Genet."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib3","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","article-title":"Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217","volume":"37","author":"Benn","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib4","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/eurheartj\/eht015","article-title":"Diagnosis and treatment of familial hypercholesterolaemia","volume":"34","author":"Hovingh","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/14779072.6.4.567","article-title":"Familial hypercholesterolemia: current treatment and advances in management","volume":"6","author":"Huijgen","year":"2008","journal-title":"Expet Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jacc.2015.11.021","article-title":"Statin initiation during childhood in patients with familial hypercholesterolemia: consequences for cardiovascular risk","volume":"67","author":"Braamskamp","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib7","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib8","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the american heart association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib9","article-title":"Familial hypercholesterolaemia: summary of NICE guidance","volume":"337","author":"Wierzbicki","year":"2008","journal-title":"BMJ Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacl.2014.01.002","article-title":"Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation","volume":"8","author":"Watts","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib11","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2016.04.054","article-title":"Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality","volume":"68","author":"Besseling","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib13","first-page":"178","article-title":"South African dyslipidaemia guideline consensus statement","volume":"102","author":"Klug","year":"2012","journal-title":"S.\u00a0Afr. Med. J.\u00a0= S.-Afr. Tydskr. Geneeskd."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib14","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/humu.21258","article-title":"Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia","volume":"31","author":"Huijgen","year":"2010","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib15","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1093\/eurheartj\/ehs038","article-title":"Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants","volume":"33","author":"Huijgen","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib16","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009220","article-title":"Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal","volume":"5","author":"Huijgen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCGENETICS.111.962456","article-title":"Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH","volume":"5","author":"Huijgen","year":"2012","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/CIRCGENETICS.110.959239","article-title":"Assessment of carotid atherosclerosis in normocholesterolemic individuals with proven mutations in the low-density lipoprotein receptor or apolipoprotein B genes","volume":"4","author":"Huijgen","year":"2011","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib20","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","author":"Santos","year":"2016","journal-title":"The Lancet Diabetes & Endocrinology."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016721","article-title":"Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated","volume":"6","author":"Leren","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib23","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.atherosclerosis.2014.02.021","article-title":"Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects","volume":"234","author":"Beliard","year":"2014","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.06.820_bib25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCGENETICS.116.001381","article-title":"Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the cascade-FH registry","volume":"9","author":"deGoma","year":"2016","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib26","doi-asserted-by":"crossref","unstructured":"Hartgers ML, Besseling J, Stroes ES, Wittekoek J, Rutten JHW, de Graaf J, Visseren FLJ, Imholz BPM, Roeters van Lennep JE, Huijgen R, Kastelein JJP, Hovingh GK. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. J. Clin. Lipidol.. in press https:\/\/doi.org\/10.1016\/j.jacl.2018.04.002.","DOI":"10.1016\/j.jacl.2018.04.002"},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib27","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib28","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.06.820_bib29","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add nonstatin therapy: a quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501831133X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501831133X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T14:37:55Z","timestamp":1565275075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191501831133X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":29,"alternative-id":["S002191501831133X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.820","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}